论文部分内容阅读
目的探讨中晚期原发性肝癌患者综合治疗后血清甲胎蛋白(AFP)水平与预后的相关性。方法选择57例AFP阳性(AFP>500 ng/ml)的中晚期原发性肝癌患者,综合治疗后定期检测血清AFP,治疗后AFP下降者为A组,治疗后AFP上升者分为B组,(判断治疗后AFP上升或下降的标准以治疗前AFP值差±10%以上)。结果 32例(A组)患者AFP有不同程度的降低,25例(B组)患者AFP有不同程度升高。A组患者的中位生存时间为10.6个月,而B组的中位生存时间为5.1个月,两组差异有统计学意义(P﹤0.01)。结论血清中AFP水平可以作为判断肝癌患者综合治疗后的预后指标。
Objective To investigate the correlation between the level of serum alpha-fetoprotein (AFP) and the prognosis of patients with advanced primary liver cancer after comprehensive treatment. Methods 57 AFP positive (AFP> 500 ng / ml) patients with advanced primary hepatocellular carcinoma (HCC) were enrolled in this study. Serum AFP was detected regularly after treatment. AFP decreased after treatment. The AFP rise was divided into B group, (To determine the standard AFP rise or fall after treatment to the pre-treatment AFP values ?? ± 10% or more). Results The AFP levels of 32 patients (group A) were decreased to some extent. The AFP levels of 25 patients (group B) were increased to some extent. The median survival time in group A was 10.6 months, while the median survival time in group B was 5.1 months. The difference between the two groups was statistically significant (P <0.01). Conclusion Serum AFP levels can be used as a prognostic indicator for the treatment of hepatocellular carcinoma after comprehensive treatment.